CoChat

Impact of chronic obstructive pulmonary disease (COPD) in the Asia-Pacific region: the EPIC Asia population-based survey

Open access

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Chronic obstructive pulmonary disease (COPD) is a clinical syndrome encompassing a group of chronic, progressive, and debilitating respiratory conditions, that are characterized by incompletely reversible airflow limitation. Within the Asia-Pacific region, prevalence estimates have been derived using various protocols and study methods, and there is little data on the impact of COPD exacerbations. This study aimed to provide a comprehensive picture of the current prevalence and burden of COPD in this region. METHODS: A population-based survey was conducted in nine Asia-Pacific territories between 01 February 2012 and 16 May 2012. Overall, 112,330 households were screened to identify eligible subjects (aged ≥40 years, with a physician diagnosis of COPD, chronic bronchitis or emphysema, or with identifiable symptoms of chronic bronchitis). Out of a sample of 69,279 individuals aged ≥40 years, 4,289 subjects with COPD were identified. Data were collected via face-to-face interviews or by fixed-line telephone, using a structured questionnaire. A total of 1,841 completed questionnaires were analyzed. RESULTS: The overall estimated COPD prevalence was 6.2%, with 19.1% of subjects having severe COPD. In the 12 months prior to the survey, nearly half of all subjects (46%) had experienced exacerbations, and 19% had been hospitalized as a result of their condition. When subjects were asked about the impact of their condition on employment, 23% said their condition kept them from working, and 42% felt that their condition limited their ability to work or their activities. Of those who reported taking prescription drugs, 20% did not know the name of the drugs they were taking. Prescription of oral corticosteroids was common, with 44% of subjects having used these during the previous year to manage their respiratory symptoms; in contrast, inhaler use was low (25%). Only 37% of subjects had taken a lung function test, and the majority (89%) of those tested did not know their test results. CONCLUSIONS: Across the Asia-Pacific territories surveyed, the prevalence of COPD is high, indicating a substantial socioeconomic burden. Our findings suggest that there is considerable room for improvement in the management of COPD, and highlight a need to enhance patient and physician education in the region.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12930-015-0020-9

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Sampling strategy and response rate for the EPIC Asia survey. ‘Study subjects’ refers to the subset of individuals aged ≥40 years who were identified as having COPD, based on the definitions used in this study (see Methods), and who completed the questionnaire.
Figure 1 Sampling strategy and response rate for the EPIC Asia survey. ‘Study subjects’ refers to the subset of individuals aged ≥40 years who were identified as having COPD, based on the definitions used in this study (see Methods), and who completed the questionnaire.CC BY · PubMed Central
Figure 2 Prevalence, frequency, and seasonal variation of exacerbations. (A) Proportion of study subjects who reported experiencing one or more exacerbations within the 12 months prior to the survey. (B) Median number of exacerbations reported by subjects over this period. (C) Proportion of subjects who reported exacerbations within each month over this period.
Figure 2 Prevalence, frequency, and seasonal variation of exacerbations. (A) Proportion of study subjects who reported experiencing one or more exacerbations within the 12 months prior to the survey. (B) Median number of exacerbations reported by subjects over this period. (C) Proportion of subjects who reported exacerbations within each month over this period.CC BY · PubMed Central
Figure 3 Unplanned healthcare utilization. (A) Proportion of subjects who either visited a hospital emergency room or made unscheduled visit(s) to a doctor or clinic as a result of their condition, in the 12 months prior to the survey. (B) Subjects who had ever been hospitalized because of their condition (n; %) were asked how many times they had been hospitalized in the previous 12 months. The proportions of subjects who had been hospitalized 0, 1, 2, or 3 or more times are indicated by the shading within each bar. Results are shown only for subjects who were able to report the number of times they had been hospitalized.
Figure 3 Unplanned healthcare utilization. (A) Proportion of subjects who either visited a hospital emergency room or made unscheduled visit(s) to a doctor or clinic as a result of their condition, in the 12 months prior to the survey. (B) Subjects who had ever been hospitalized because of their condition (n; %) were asked how many times they had been hospitalized in the previous 12 months. The proportions of subjects who had been hospitalized 0, 1, 2, or 3 or more times are indicated by the shading within each bar. Results are shown only for subjects who were able to report the number of times they had been hospitalized.CC BY · PubMed Central
Figure 4 Impact of disease on employment and work productivity. (A) Employment status of study subjects. (B) Proportion of subjects who reported that their condition kept them from working, limited the kind or amount of work they could do, or limited their activities. (C) Subjects’ estimated level of productivity on a typical day, and on a day when symptoms are at their worst. Upper row of n values: subjects who answered the question regarding productivity on a typical day; lower row of n values: subjects who answered the question regarding their worst day.
Figure 4 Impact of disease on employment and work productivity. (A) Employment status of study subjects. (B) Proportion of subjects who reported that their condition kept them from working, limited the kind or amount of work they could do, or limited their activities. (C) Subjects’ estimated level of productivity on a typical day, and on a day when symptoms are at their worst. Upper row of n values: subjects who answered the question regarding productivity on a typical day; lower row of n values: subjects who answered the question regarding their worst day.CC BY · PubMed Central
Figure 5 Delivery format of prescribed medication. Subjects who reported taking a prescription drug were asked about the delivery format of their medication. Numbers below the bars indicate the total number of valid answers for this question, for the corresponding territory. Results are shown only for subjects who were able to report the delivery format of their medication.
Figure 5 Delivery format of prescribed medication. Subjects who reported taking a prescription drug were asked about the delivery format of their medication. Numbers below the bars indicate the total number of valid answers for this question, for the corresponding territory. Results are shown only for subjects who were able to report the delivery format of their medication.CC BY · PubMed Central
Figure 6 Use of oral corticosteroids. All study subjects (upper row of n values) were asked if they had been told to use oral steroids to manage their respiratory symptoms in the past 12 months. Those who had been prescribed steroids (lower row of n values) were asked if they had been told to take the steroids for three days or longer.
Figure 6 Use of oral corticosteroids. All study subjects (upper row of n values) were asked if they had been told to use oral steroids to manage their respiratory symptoms in the past 12 months. Those who had been prescribed steroids (lower row of n values) were asked if they had been told to take the steroids for three days or longer.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 27 references

Cited by

See all 167

Metadata

Authors
Lim, S., Lam, D. C.-L., Muttalif, A. R., Yunus, F., Wongtim, S., Lan, L. T. T., Shetty, V., Chu, R., Zheng, J., Perng, D.-W., & de Guia, T.
Affiliations
  • National University of Singapore (SG)
  • University of Hong Kong (HK)
  • University of Indonesia (ID)
  • Chulalongkorn University (TH)
  • University Medical Center HCMC (VN)
  • Takeda (Singapore) (SG)
  • First Affiliated Hospital of Guangzhou Medical University (CN)
  • Taipei Veterans General Hospital (TW)
Corresponding author
Lim, Sam
Venue
Asia Pacific Family Medicine
Published
2015-04-23
Volume
14
Issue
1
Pages
4-4
ISSN
  • 1444-1683 (ISSN-L)
  • 1447-056X
OpenAlex
W2010316074
Cited by
167
References
27
Citations by year
2026: 5 · 2025: 11 · 2024: 14 · 2023: 19 · 2022: 12 · 2021: 24 · 2020: 17 · 2019: 22 · 2018: 20 · 2017: 13 · 2016: 7 · 2015: 3
FWCI
11.34
Type
journal article
Language
en
Open access
Locations
  • Asia Pacific Family Medicine (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • The HKU Scholars Hub (University of Hong Kong) (submittedVersion, cc-by-nc-nd)
  • Greater South Information System
Funders
Takeda Pharmaceuticals International
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
Keywords
chronic obstructive pulmonary disease, COPD prevalence, COPD exacerbations, COPD hospitalization, socioeconomic burden, employment effects, oral corticosteroids, inhaler use, pulmonary function tests, COPD management, Asia-Pacific region

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Impact of chronic obstructive pulmonary disease (COPD) in the Asia-Pacific region: the EPIC Asia population-based survey. https://app.cochat.ai/papers/10.1186/s12930-015-0020-9
The paper
Lim, S., Lam, D. C.-L., Muttalif, A. R., Yunus, F., Wongtim, S., Lan, L. T. T., Shetty, V., Chu, R., Zheng, J., Perng, D.-W., & de Guia, T. (2015). Impact of chronic obstructive pulmonary disease (COPD) in the Asia-Pacific region: the EPIC Asia population-based survey. Asia Pacific Family Medicine. https://doi.org/10.1186/s12930-015-0020-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.